Investor Presentation

Webcast
  • 13
    2024-03
    Abbisko FY23 Annual Results Conference (Chinese Session)
    Click to the Webcast
  • 05
    2023-12
    Abbisko Enters Into An Exclusive License Agreement With Merck For Pimicotinib Conference Call (Chinese Session)
    09:00
    Click to the Webcast
  • 25
    2023-10
    ESMO&AACR-NCI-EORTC Updated Data (Chinese Session)
    09:00
    Click to the Webcast
  • 16
    2023-03
    FY22 Annual Results Video Conference Call (Bilingual Sessions)
    08:30
    Click to the Webcast
  • 23
    2022-08
    2022 Interim Results Video Conference Call (English Session)
    08:00
    Click to the Webcast
  • 21
    2022-03
    FY21 Annual Results Conference Call (Chinese Session)
    14:00
    Click to the Webcast
  • 21
    2022-03
    FY21 Annual Results Conference Call (English Session)
    10:00
    Click to the Webcast
Presentation Materials
  • Company Presentation
  • FY23 Annual Results Presentation
  • Abbisko Therapeutics Announces an Exclusive Licensing-out Agreement for Pimicotinib (ABSK021)
  • ESMO&AACR-NCI-EORTC Updated Data
  • 1H23 Interim Results Presentation
  • 2022 Full Year Results and Business Updates Presentation
  • Clinical Data Readout for ABSK021
  • 1H 2022 Interim Results Presentation
  • 2021 Full Year Results and Business Updates Presentation

Copyright © 2021 All rights reserved:Abbisko Therapeautics     沪ICP备17056565号   

Lang
En